Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Mar 21, 2017
Arbutus Announces Year-End 2016 Financial Results
Mar 21, 2017 at 2:00 PM ET
Arbutus Year-End 2016 Financial Results Conference Call
Mar 14, 2017
Barclays Global Healthcare Conference